Statement Of Deviation & Variation
Filed with BSE · · 3 pages · English
Sub: Statement of deviation or variation in the use of proceeds raised through Preferential Issue Venkata Rao Sadhanala Managing Director Statement of Deviation / Variation in utilization of funds raised: Annexure A Objects for which funds have been raised: Venkata Rao Sadhanala Managing Director
Venmax Drugs & Pharmaceuticals Ltd. on 6ix
Earlier from Venmax Drugs & Pharmaceuticals
- Unaudited Financial Results For The Quarter Ended June 30, 2026.
- Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended June 30, 2026.
- Venmax Drugs & Pharmaceuticals Ltd. Press Release Aug 01 2026
- Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended June 30, 2026.
- Venmax Drugs & Pharmaceuticals Ltd. Press Release Jul 29 2026
Later from Venmax Drugs & Pharmaceuticals
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Venmax Drugs & Pharmaceuticals Ltd. Press Release Aug 08 2026
- Board Meeting Intimation for Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
- Venmax Drugs & Pharmaceuticals Ltd. Press Release Aug 24 2026
- Board Meeting Outcome for Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Follow Venmax Drugs & Pharmaceuticals into a list and get an email when it puts out news.
Follow Venmax Drugs & Pharmaceuticals